What is Juno Research?
Established in 2004, Juno Research LLC specializes in conducting Phases I through IV clinical trials. The company provides high-quality study services to a diverse clientele, including pharmaceutical firms, contract research organizations, and biotechnology companies. Juno Research distinguishes itself through competitive pricing and a steadfast commitment to delivering quality data essential for effective drug development. Its operations are supported by a team of seasoned investigators and regulatory coordinators, who ensure rigorous adherence to regulatory standards and robust internal quality controls. The company's mission is to enhance the drug development pipeline while cultivating an environment that champions diversity and fosters innovation.
How much funding has Juno Research raised?
Juno Research has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in Juno Research
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Juno Research?
With the recent influx of capital, Juno Research is poised for accelerated growth and expansion within the competitive clinical research landscape. The large-scale, late-stage funding suggests a strategic focus on scaling operations, potentially enhancing its service offerings, and broadening its market reach. This investment will likely empower the company to undertake more complex trials, invest in advanced research technologies, and strengthen its partnerships within the pharmaceutical and biotech sectors. Juno Research's commitment to quality and regulatory compliance, coupled with its strategic financial backing, positions it for continued success in advancing drug development.
See full Juno Research company page
